Germany-based Boehringer Ingelheim and United States-based Eli Lilly and Company have signed an academic collaboration with the University of Oxford.

It was reported yesterday that the collaboration is aimed at assessing the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.

EMPA-KIDNEY will EMPA-KIDNEY will include approximately 5,000 people with established chronic kidney disease, with and without diabetes and will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes.

The study will be independently conducted, analysed and reported by the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU), which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit. Boehringer Ingelheim and Eli Lilly and Company will provide the funding for the study. The study will be part of the empagliflozin clinical development programme, the largest clinical development programme of an SGLT2 inhibitor.